

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7402793/publications.pdf Version: 2024-02-01



ΤΛΙ ΥΙ

#	Article	IF	CITATIONS
1	Electrospun Tissue-Engineered Arterial Graft Thickness Affects Long-Term Composition and Mechanics. Tissue Engineering - Part A, 2021, 27, 593-603.	3.1	11
2	Sex and Tamoxifen confound murine experimental studies in cardiovascular tissue engineering. Scientific Reports, 2021, 11, 8037.	3.3	11
3	Surgery and Sample Processing for Correlative Imaging of the Murine Pulmonary Valve. Journal of Visualized Experiments, 2021, , .	0.3	0
4	Zoledronate alters natural progression of tissueâ€engineered vascular grafts. FASEB Journal, 2021, 35, e21849.	0.5	3
5	Different degradation rates of nanofiber vascular grafts in small and large animal models. Journal of Tissue Engineering and Regenerative Medicine, 2020, 14, 203-214.	2.7	25
6	Effects of Braiding Parameters on Tissue Engineered Vascular Graft Development. Advanced Healthcare Materials, 2020, 9, e2001093.	7.6	18
7	Tissue Engineered Vascular Graft Recipient Interleukin 10 Status Is Critical for Preventing Thrombosis. Advanced Healthcare Materials, 2020, 9, e2001094.	7.6	8
8	Imatinib attenuates neotissue formation during vascular remodeling in an arterial bioresorbable vascular graft. JVS Vascular Science, 2020, 1, 57-67.	1.1	5
9	Fetal Transcatheter Trileaflet Heart Valve Hemodynamics: Implications of Scaling on Valve Mechanics and Turbulence. Annals of Biomedical Engineering, 2020, 48, 1683-1693.	2.5	4
10	Early natural history of neotissue formation in tissue-engineered vascular grafts in a murine model. Regenerative Medicine, 2019, 14, 389-408.	1.7	23
11	A Correlative Imaging Approach for Extracellular Matrix Characterization in Mice. Microscopy and Microanalysis, 2019, 25, 1134-1135.	0.4	0
12	Differential outcomes of venous and arterial tissue engineered vascular grafts highlight the importance of coupling long-term implantation studies with computational modeling. Acta Biomaterialia, 2019, 94, 183-194.	8.3	34
13	Implantation of VECFâ€functionalized cellâ€free vascular grafts: regenerative and immunological response. FASEB Journal, 2019, 33, 5089-5100.	0.5	38
14	Oversized Biodegradable Arterial Grafts Promote Enhanced Neointimal Tissue Formation. Tissue Engineering - Part A, 2018, 24, 1251-1261.	3.1	12
15	Intratumoral Delivery of InterferonÎ <sup>3</sup> -Secreting Mesenchymal Stromal Cells Repolarizes Tumor-Associated Macrophages and Suppresses Neuroblastoma Proliferation In Vivo. Stem Cells, 2018, 36, 915-924.	3.2	55
16	Role of Bone Marrow Mononuclear Cell Seeding for Nanofiber Vascular Grafts. Tissue Engineering - Part A, 2018, 24, 135-144.	3.1	36
17	Immuno-driven and Mechano-mediated Neotissue Formation in Tissue Engineered Vascular Grafts. Annals of Biomedical Engineering, 2018, 46, 1938-1950.	2.5	51
18	Angiotensin II receptor I blockade prevents stenosis of tissue engineered vascular grafts. FASEB Journal, 2018, 32, 6822-6832.	0.5	13

ΤΑΙ ΥΙ

#	Article	IF	CITATIONS
19	Bone marrow-derived mononuclear cell seeded bioresorbable vascular graft improves acute graft patency by inhibiting thrombus formation via platelet adhesion. International Journal of Cardiology, 2018, 266, 61-66.	1.7	13
20	The role of myeloid cell-derived PDGF-B in neotissue formation in a tissue-engineered vascular graft. Regenerative Medicine, 2017, 12, 249-261.	1.7	16
21	Tropoelastin inhibits intimal hyperplasia of mouse bioresorbable arterial vascular grafts. Acta Biomaterialia, 2017, 52, 74-80.	8.3	33
22	Deconstructing the Tissue Engineered Vascular Graft: Evaluating Scaffold Pre-Wetting, Conditioned Media Incubation, and Determining the Optimal Mononuclear Cell Source. ACS Biomaterials Science and Engineering, 2017, 3, 1972-1979.	5.2	22
23	Fast-degrading bioresorbable arterial vascular graft with high cellular infiltration inhibits calcification of the graft. Journal of Vascular Surgery, 2017, 66, 243-250.	1.1	50
24	Novel application and serial evaluation of tissue-engineered portal vein grafts in a murine model. Regenerative Medicine, 2017, 12, 929-938.	1.7	4
25	Rational design of an improved tissue-engineered vascular graft: determining the optimal cell dose and incubation time. Regenerative Medicine, 2016, 11, 159-167.	1.7	29
26	TGFâ€Î² receptor 1 inhibition prevents stenosis of tissueâ€engineered vascular grafts by reducing host mononuclear phagocyte activation. FASEB Journal, 2016, 30, 2627-2636.	0.5	26
27	Engineered Tissue–Stent Biocomposites as Tracheal Replacements. Tissue Engineering - Part A, 2016, 22, 1086-1097.	3.1	30
28	Pilot Mouse Study of 1 mm Inner Diameter (ID) Vascular Graft Using Electrospun Poly(ester urea) Nanofibers. Advanced Healthcare Materials, 2016, 5, 2427-2436.	7.6	29
29	Novel Bioresorbable Vascular Graft With Sponge-Type Scaffold as a Small-Diameter Arterial Graft. Annals of Thoracic Surgery, 2016, 102, 720-727.	1.3	43
30	Long-Term Functional Efficacy of a Novel Electrospun Poly(Glycerol Sebacate)-Based Arterial Graft in Mice. Annals of Biomedical Engineering, 2016, 44, 2402-2416.	2.5	71
31	Tissue-Engineered Small Diameter Arterial Vascular Grafts from Cell-Free Nanofiber PCL/Chitosan Scaffolds in a Sheep Model. PLoS ONE, 2016, 11, e0158555.	2.5	156
32	Hemodynamic Characterization of a Mouse Model for Investigating the Cellular and Molecular Mechanisms of Neotissue Formation in Tissue-Engineered Heart Valves. Tissue Engineering - Part C: Methods, 2015, 21, 987-994.	2.1	15
33	The innate immune system contributes to tissueâ€engineered vascular graft performance. FASEB Journal, 2015, 29, 2431-2438.	0.5	58
34	Comparison of the Biological Equivalence of Two Methods for Isolating Bone Marrow Mononuclear Cells for Fabricating Tissue-Engineered Vascular Grafts. Tissue Engineering - Part C: Methods, 2015, 21, 597-604.	2.1	15
35	Interferon-γ–Mediated Allograft Rejection Exacerbates Cardiovascular Disease of Hyperlipidemic Murine Transplant Recipients. Circulation Research, 2015, 117, 943-955.	4.5	12
36	A mouse model of endocardial fibroelastosis. Cardiovascular Pathology, 2015, 24, 388-394.	1.6	4

ΤΑΙ ΥΙ

#	Article	IF	CITATIONS
37	Cilostazol, Not Aspirin, Prevents Stenosis of Bioresorbable Vascular Grafts in a Venous Model. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2003-2010.	2.4	17
38	Evaluation of remodeling process in small-diameter cell-free tissue-engineered arterial graft. Journal of Vascular Surgery, 2015, 62, 734-743.	1.1	52
39	Development of Small Diameter Nanofiber Tissue Engineered Arterial Grafts. PLoS ONE, 2015, 10, e0120328.	2.5	56
40	Well-organized neointima of large-pore poly(l-lactic acid) vascular graft coated with poly(l-lactic-co-ε-caprolactone) prevents calcific deposition compared to small-pore electrospun poly(l-lactic acid) graft in a mouse aortic implantation model. Atherosclerosis, 2014, 237, 684-691.	0.8	75
41	Implantation of Inferior Vena Cava Interposition Graft in Mouse Model. Journal of Visualized Experiments, 2014, , .	0.3	20
42	Transplantation of Pulmonary Valve Using a Mouse Model of Heterotopic Heart Transplantation. Journal of Visualized Experiments, 2014, , .	0.3	6
43	A critical role for macrophages in neovessel formation and the development of stenosis in tissueâ€engineered vascular grafts. FASEB Journal, 2011, 25, 4253-4263.	0.5	199
44	Tissue-engineered vascular grafts: does cell seeding matter?. Journal of Pediatric Surgery, 2010, 45, 1299-1305.	1.6	62
45	Small-diameter biodegradable scaffolds for functional vascular tissue engineering in the mouse model. Biomaterials, 2008, 29, 1454-1463.	11.4	160
46	Amelioration of Human Allograft Arterial Injury by Atorvastatin or Simvastatin Correlates With Reduction of Interferon-Î <sup>3</sup> Production by Infiltrating T Cells. Transplantation, 2008, 86, 719-727.	1.0	18
47	Nogoâ€B limits intimaâ€media thickening during mouse vein graft adaptation. FASEB Journal, 2008, 22, 174.4.	0.5	0
48	Human Allograft Arterial Injury Is Ameliorated by Sirolimus and Cyclosporine and Correlates with Suppression of Interferon-??. Transplantation, 2006, 81, 559-566.	1.0	21